MX2021010021A - Proteínas sintéticas autoensamblables. - Google Patents

Proteínas sintéticas autoensamblables.

Info

Publication number
MX2021010021A
MX2021010021A MX2021010021A MX2021010021A MX2021010021A MX 2021010021 A MX2021010021 A MX 2021010021A MX 2021010021 A MX2021010021 A MX 2021010021A MX 2021010021 A MX2021010021 A MX 2021010021A MX 2021010021 A MX2021010021 A MX 2021010021A
Authority
MX
Mexico
Prior art keywords
self
present disclosure
immunogenic
limited
antigens
Prior art date
Application number
MX2021010021A
Other languages
English (en)
Inventor
Daniel T Verhamme
Keith Alan Charlton
Erik D´HONDT
Original Assignee
Bioven 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioven 3 Ltd filed Critical Bioven 3 Ltd
Publication of MX2021010021A publication Critical patent/MX2021010021A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación prové una proteína inmunogénica sintética para uso como un agente inmunomodulador para mejorar las reacciones inmunes de mamíferos hacia proteína conjugada o péptido que contiene antígenos que son de otra manera poco inmunogénicos, incluyendo, pero no limitado a auto-antígenos. Las proteínas inmunogénicas quiméricas de la presente divulgación se pueden utilizar en el tratamiento de muchas enfermedades, incluyendo, pero no limitado a, cánceres, enfermedades infecciosas, enfermedades autoinmunes, alergias y cualquier indicación clínica que se ve implicada o afectada por la inmunorespuesta de un hospedero mamífero.
MX2021010021A 2013-03-15 2015-09-11 Proteínas sintéticas autoensamblables. MX2021010021A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791268P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
MX2021010021A true MX2021010021A (es) 2021-12-10

Family

ID=51225849

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012461A MX2015012461A (es) 2013-03-15 2014-03-17 Proteinas sintéticas autoensamblables.
MX2021010021A MX2021010021A (es) 2013-03-15 2015-09-11 Proteínas sintéticas autoensamblables.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015012461A MX2015012461A (es) 2013-03-15 2014-03-17 Proteinas sintéticas autoensamblables.

Country Status (14)

Country Link
US (3) US10736948B2 (es)
EP (1) EP2970409A2 (es)
JP (1) JP6873530B2 (es)
KR (2) KR102427429B1 (es)
CN (2) CN105209481B (es)
AU (1) AU2014229561B2 (es)
BR (1) BR112015023402A2 (es)
CA (1) CA2904506A1 (es)
HK (1) HK1214606A1 (es)
IL (3) IL286537B (es)
MX (2) MX2015012461A (es)
MY (1) MY187936A (es)
RU (1) RU2747857C2 (es)
WO (1) WO2014140894A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160333087A1 (en) 2015-05-12 2016-11-17 Bioven 3 Limited Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
CN111246878A (zh) * 2017-07-18 2020-06-05 因斯瑞拜奥有限公司 合成蛋白及其治疗用途
KR20220058527A (ko) * 2019-06-25 2022-05-09 인3바이오 리미티드 안정화된 키메라 합성 단백질 및 그 치료 용도
WO2021090069A1 (en) 2019-11-07 2021-05-14 In3Bio Ltd. Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors
CN114019166B (zh) * 2021-09-27 2024-02-27 浙江省食品药品检验研究院 一种检测龙葵素的试纸条及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US6153203A (en) 1993-10-08 2000-11-28 Duotol Ab Immunological tolerance-inducing agent
EP0657175B1 (en) * 1993-12-09 2005-03-02 Centro de Inmunologia Molecular Vaccine comprising human autologous epidermal growth factor and use thereof
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AU729579B2 (en) 1996-10-23 2001-02-01 Trustees Of The University Of Pennsylvania, The Immunotherapy and improved vaccines
EP1009429B1 (en) 1997-08-29 2009-07-08 Antigenics Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US20080249019A1 (en) * 1998-08-25 2008-10-09 Syntaxin, Ltd. Treatment of mucus hypersecretion
EP2322210A1 (en) 1999-04-19 2011-05-18 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CA2385172A1 (en) 1999-10-08 2001-04-19 Active Biotech Ab Ab5 toxin b subunit mutants with altered chemical conjugation characteristics
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
EP1452556B1 (en) 2001-06-21 2009-06-10 Teijin Limited Near infrared ray shielding film
GB0115382D0 (en) 2001-06-22 2001-08-15 Univ Bristol Mutant
EP1490481A4 (en) * 2001-12-14 2005-12-07 Centocor Inc CLONAL CELL LINES OF MYELOMES FOR PRODUCING PROTEINS IN A CHEMICALLY DEFINED ENVIRONMENT
DK1485475T3 (da) * 2002-03-15 2008-01-21 Cellectis Hybrid meganuklease og enkeltkædet maganuklease og brug deraf
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
JP4623625B2 (ja) 2003-07-24 2011-02-02 株式会社ＡＭＢｉＳ ヘテロ型５量体組換えワクチン
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
EP1696945B1 (en) * 2003-12-05 2012-01-18 Northwestern University Self-assembling peptide amphiphiles and related methods for growth factor delivery
EP1716173B8 (en) 2004-02-11 2012-06-27 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Carcinoembryonic antigen fusion protein and uses thereof
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
JP2011501946A (ja) 2007-10-25 2011-01-20 ヴィヴェンティア バイオテクノロジーズ インコーポレーティッド 変異体ＨｎＲＮＰＧの癌関連エピトープに対する抗体およびその使用法
JP2011507511A (ja) 2007-12-19 2011-03-10 ミヴァック ディベロップメント アクティエボラグ 自己免疫疾患及びアレルギー性疾患の治療用組成物及び方法
RU2509570C2 (ru) 2008-06-09 2014-03-20 Бхарат Байотек Интернэшнл Лимитед Вакцинная композиция, пригодная при инфекциях hpv и вирусом гепатита в, и способ ее получения
JP2010050586A (ja) 2008-08-20 2010-03-04 Nec Corp 通信装置及びそれに用いる装置コンポーネント複合冗長化方法
CN102272302B (zh) * 2008-10-31 2015-04-15 生物载体株式会社 增强重组蛋白表达的方法
RU2593720C2 (ru) * 2008-12-19 2016-08-10 Макродженикс, Инк. Ковалентные диантитела и их применение
JP2011097930A (ja) * 2009-10-07 2011-05-19 Hokkaido Univ 光活性化生理機能センサータンパク質
RU2480524C2 (ru) * 2010-09-13 2013-04-27 Учреждение Российской академии наук Институт биоорганической химии им. академии М.М. Шемякина и Ю.А. Овчинникова РАН Конструкция на основе белковой пары барназа-барстар и способ ее получения
CA2828811C (en) * 2011-03-03 2021-09-21 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
CN102604993B (zh) 2012-01-10 2013-03-20 天津耀宇生物技术有限公司 免疫佐剂与幽门螺杆菌抗原融合蛋白口服疫苗及其制备方法

Also Published As

Publication number Publication date
KR102391734B1 (ko) 2022-04-29
IL241116A0 (en) 2015-11-30
HK1214606A1 (zh) 2016-07-29
RU2015143217A (ru) 2017-04-27
US10736948B2 (en) 2020-08-11
MY187936A (en) 2021-10-29
US11419923B2 (en) 2022-08-23
KR20150139513A (ko) 2015-12-11
CN111978409A (zh) 2020-11-24
IL286537A (en) 2021-10-31
AU2014229561A1 (en) 2015-10-29
KR102427429B1 (ko) 2022-08-01
WO2014140894A2 (en) 2014-09-18
BR112015023402A2 (pt) 2017-08-22
KR20210005294A (ko) 2021-01-13
RU2019109120A (ru) 2019-06-13
AU2014229561B2 (en) 2018-06-07
MX2015012461A (es) 2016-08-08
CN111978409B (zh) 2024-01-26
WO2014140894A3 (en) 2015-02-19
JP6873530B2 (ja) 2021-05-19
RU2747857C2 (ru) 2021-05-17
IL273051B (en) 2021-10-31
IL241116B (en) 2020-03-31
CN105209481B (zh) 2020-08-25
IL286537B (en) 2022-07-01
US20230042534A1 (en) 2023-02-09
IL273051A (en) 2020-04-30
JP2016517402A (ja) 2016-06-16
US20200297827A1 (en) 2020-09-24
CA2904506A1 (en) 2014-09-18
EP2970409A2 (en) 2016-01-20
US20160095910A1 (en) 2016-04-07
CN105209481A (zh) 2015-12-30

Similar Documents

Publication Publication Date Title
MX2021010021A (es) Proteínas sintéticas autoensamblables.
PH12015501092A1 (en) Anti-ceacam5 antibodies and uses thereof
CR20140565A (es) Proteínas de fusión de interleuquina 10 y usos de las mismas
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
TR201910103T4 (tr) Anti-fcrn antikorları.
NZ714163A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
TN2012000167A1 (en) Human il-23 antigen binding proteins
EA201491784A1 (ru) Антитела против лигандов рецептора в1 брадикинина
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
PH12016502430A1 (en) Method for decreasing immunogenicity of protein and peptide
PH12016500753A1 (en) Antibodies specific to fcrn
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
EA201591796A1 (ru) Антитела к cd52
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
MX2016004754A (es) Nuevo peptido que tiene cuatro epitopos de linfocitos t citotoxicos (ctl) enlazados.
MX349653B (es) Vacunógeno de ospc quimérico polivalente y antígeno de diagnóstico.
MX2015011257A (es) Peptido novedoso que tiene 5 epitopos de linfocitos t citotoxicos enlazados.
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.
PL401502A1 (pl) Epitop i jego zastosowanie
NZ733839A (en) Amino acid and peptide conjugates and conjugation process